-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Peripheral T-cell lymphoma (PTCL) is a non-Hodgkin lymphoma (NHL).
In Western countries, the incidence of PTCL accounts for 5%-10% of NHL, and it is even higher in Asian and South American countries, reaching 15%.
-20%
.
In addition, patients with PTCL face multiple problems that urgently need to be resolved, such as low survival rate, high recurrence rate, and single treatment
.
Two clinical studies on PTCL by Professor Qingqing Cai’s team from the Cancer Center of Sun Yat-sen University have obtained very gratifying results, and they will be presented at the 2021 EHA conference in the form of a poster
.
Yimaitong invited Professor Cai Qingqing to introduce the development of PTCL
.
Yimaitong: What is the current status of treatment of peripheral T-cell lymphoma in my country? What are the unmet clinical needs? Professor Qingqing Cai’s PTCL is a heterogeneous aggressive non-Hodgkin’s lymphoma, which is mostly advanced and progressing rapidly when first diagnosed.
Even with high-intensity treatment, the cure rate is still low
.
The most common first-line treatment for PTCL is cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or CHOP-like regimens
.
The ECHELON-2 study established the CD30-targeting antibody-drug conjugate (ADC) Verbutuximab (BV) combined with CHP as the first-line treatment for CD30-positive PTCL.
The median progression-free survival (PFS) of this program ) Reached 48.
2 months, much higher than the 20.
8 months of traditional chemotherapy
.
However, in CD30-negative patients, the best combination medication strategy still needs to be further explored
.
Patients with relapsed and refractory peripheral T-cell lymphoma (RR PTCL) still lack effective treatment drugs, and the clinical outcome is poor
.
In the era of traditional chemotherapy, the median overall survival (OS) and PFS of patients with RR PTCL were only 6.
5 months and 3.
1 months, respectively
.
How to improve the efficacy of RR PTCL patients requires more treatment drugs and strategies
.
Around the world, several new drugs are approved for the treatment of RR PTCL, such as Pratroxa, Romidepsin, Belirestat, Forodesine, Chidamide, and BV
.
However, many of the new drugs mentioned above have not yet been approved in China.
Until 2020, BV and Pratroxa are officially approved in China
.
Chidamide, as an oral histone deacetylase (HDAC) inhibitor, is the most widely used targeted drug in RR PTCL in China
.
Key Phase II studies and post-marketing studies suggest that the effective rates of chidamide in the treatment of RR PTCL are 28% and 47%, respectively, and the effective rate of combination therapy may be higher
.
However, in general, there are relatively few options for PTCL treatment drugs.
How to use existing drugs reasonably to improve the efficacy of PTCL is still a problem worthy of attention in the current clinical practice of PTCL
.
Yimaitong: At this EHA meeting, you and your team reported on a study of chidamide combined with CHOP versus CHOP in the first-line treatment of PTCL.
The preliminary data is gratifying.
Could you please interpret this study in detail? Professor Qingqing Cai we retrospectively analyzed 408 newly diagnosed PTCL patients who were treated with CHOP combined with Chidamide (C-CHOP) regimen or CHOP regimen at Sun Yat-sen University Cancer Center from January 2014 to July 2020
.
According to the IPI score, the patients were matched 1:1, 22 cases were included in the C-CHOP group, and 22 cases were included in the CHOP group
.
The usage of chidamide is 20 mg twice a week
.
Patients who achieved complete remission (CR) or partial remission (PR) after treatment received maintenance therapy with chidamide
.
The study analyzed the overall response rate (ORR), PFS, OS and adverse events (AE), and explored the effectiveness and safety of the CHOP regimen and the C-CHOP regimen as the first-line treatment of PTCL
.
The median ages of patients in the C-CHOP group and CHOP group were 54.
5 years and 56.
0 years, respectively, and 10 female patients (45.
5%) and 11 female patients (50%) were enrolled, respectively
.
In the two groups of patients, IPI 0-1 and IPI≥2 were 31.
8% (7/22) and 68.
2% (15/22), respectively
.
There was no significant difference in baseline characteristics between the two groups (P>0.
05)
.
The ORR of the C-CHOP group and CHOP group were 86.
4% and 76.
3%, respectively, and the CR rates were 68.
2% and 59.
1% (P>0.
05)
.
The median follow-up was 22.
3 months.
Compared with the CHOP group, the PFS of the C-CHOP group was significantly prolonged (less than 14.
2±5.
7 months, P=0.
035)
.
However, no difference in OS was found between the two groups (P=0.
783)
.
The most common grade 3-4 AEs in the C-CHOP and CHOP groups were hematological toxicity, including neutropenia (36.
4% vs 22.
7%), thrombocytopenia (22.
7% vs 9.
0%), and anemia (22.
7% vs 4.
5 %)
.
Studies have initially shown that in the first-line treatment of PTCL patients, the C-CHOP regimen is effective and safe, and can significantly prolong PFS, but there is no difference between OS and ORR
.
In addition, we should also pay attention to the hematological toxicity of CHOP combined with Chidamide, and further clinical research is needed
.
Yimaitong: At this EHA meeting, you also reported a comparative study of the efficacy of chidamine-containing regimen vs.
chemotherapy alone in the treatment of relapsed and refractory peripheral T-cell lymphoma.
Could you please introduce the results of the study and combine it with you What is the significance of this from your own experience? Professor Qingqing Cai This study compared the efficacy of chidamide-containing regimens and chemotherapy alone in the second-line treatment of PTCL
.
We retrospectively analyzed the clinical data of 96 patients with RR PTCL who were treated at Sun Yat-sen University Cancer Center from January 2014 to July 2020
.
The inclusion criteria were relapsed patients who had received first-line treatment in the past
.
Based on the second-line treatment plan, patients are divided into three groups: chemotherapy alone group, chemotherapy combined with chidamide, chidamide with or without other targeted drugs (targeted therapy group)
.
Compare the PFS, OS, ORR, CR rates of the three groups of patients
.
With a median follow-up of 20.
1 months, the baseline data (median age, gender, second-line IPI, PTCL subtype, CD30 expression, and EBV infection) analysis of the three groups of patients found that the chemotherapy group included more PTCL non-specific types (PTCL-NOS ) Patients, the targeted therapy group included more patients with angioimmunoblastic T-cell lymphoma (AITL), and other baseline characteristics were basically balanced among the groups
.
PFS was better in the chemotherapy combined with Chidamide group (P=0.
046), (chemotherapy alone group vs chemotherapy combined with Chidamide group vs targeted therapy group: 3.
5 months vs 4.
5 months vs 1.
8 months, P=0.
046) The median PFS in the chemotherapy plus chidamide group was 4.
5 months, compared with 3.
5 months in the chemotherapy group and 1.
8 months in the targeted therapy group
.
There was no significant difference in OS between the three groups (P=0.
912)
.
Subgroup analysis showed that chemotherapy combined with Chidamide can provide high second-line IPI (3-5 points) (P=0.
045), young patients (≤60 years old) (P=0.
027) and CD30-negative (P=0.
002) patients Bring PFS benefits
.
There was no significant difference in PFS in low second-line IPI (0-2 points), elderly patients (>60 years old), and CD30-positive patients
.
In high second-line IPI patients, chemotherapy combined with Chidamide has a tendency to prolong OS (P=0.
188)
.
The ORRs of the chemotherapy group, chemotherapy combined with Chidamide group, and targeted therapy group were 54.
8%, 64.
9%, 64.
7% (P=0.
607), and the CR rates were 16.
7%, 18.
9%, and 35.
3% (P=0.
262)
.
Compared with chemotherapy alone and targeted therapy containing chidamide, chemotherapy combined with chidamide as a second-line treatment has more PFS benefits, and chidamide should be considered in the treatment of RR PTCL
.
Yimaitong: In the past two years, there have been many advances in the treatment of PTCL, including the research results you reported at this year's EHA.
What changes will these advances bring to the treatment of PTCL? In the retrospective study of the first-line treatment of PTCL by Professor Qingqing Cai, we compared the CHOP combined with Chidamide regimen and the CHOP regimen
.
Because the IPI score is an important indicator of the prognostic risk of PTCL, it is reasonable and necessary to match the cases with 1:1 according to the IPI score
.
The results of the study suggest that CHOP combined with Chidamide can bring benefits to PFS in the first-line treatment of PTCL, which is effective and safe
.
However, a large randomized study is still needed to verify the effectiveness of Chidamide in the first-line treatment of PTCL
.
In the retrospective study of RR PTCL, we retrospectively compared the curative effects of chidamide-containing regimens and chemotherapy regimens in patients with RR PTCL.
The results of the study suggest that chidamide combined with chemotherapy can be further enhanced on the basis of chemotherapy.
It is of practical significance for the treatment of PTCL
.
However, at this stage, further randomized studies are needed to confirm the effectiveness and safety of chidamide combined with chemotherapy in patients with RR PTCL
.
In general, the current treatment of PTCL, in addition to traditional chemotherapy, needs to actively consider new drugs such as verbutuximab and HDAC inhibitors to further improve the effective rate and extend the time of disease control
.
For patients with effective treatment, hematopoietic stem cell transplantation is still an important treatment method; for some patients who are not suitable for transplantation or who refuse transplantation, maintenance therapy with targeted drugs is also an optional strategy
.
Professor Cai Qingqing, Chief Physician, PhD Supervisor, Deputy Director of the Department of Internal Medicine, Sun Yat-sen University Tumor Hospital, Head of the Lymphoma Group of the Oncology Branch of the Guangdong Medical Association, Deputy Chairman of the Youth Committee of the Oncology Branch of the Chinese Medical Association, Lymphoma Major, China Medical Education Association Deputy Chairman of the Committee, Deputy Chairman of the Lymphoma Professional Committee of the Guangdong Provincial Association of Women Physicians, Deputy Chairman of the Guangdong Anti-Cancer Association, Hematological Oncology Committee, Deputy Chairman of the Youth Committee, Beijing Cancer Society ) The corresponding author has published 14 SCI papers on Blood, Leukemia, CCR, etc.
, and presided over 3 National Natural Science Funds and a number of provincial funds stamped "Read the original text", and we will make progress together
In Western countries, the incidence of PTCL accounts for 5%-10% of NHL, and it is even higher in Asian and South American countries, reaching 15%.
-20%
.
In addition, patients with PTCL face multiple problems that urgently need to be resolved, such as low survival rate, high recurrence rate, and single treatment
.
Two clinical studies on PTCL by Professor Qingqing Cai’s team from the Cancer Center of Sun Yat-sen University have obtained very gratifying results, and they will be presented at the 2021 EHA conference in the form of a poster
.
Yimaitong invited Professor Cai Qingqing to introduce the development of PTCL
.
Yimaitong: What is the current status of treatment of peripheral T-cell lymphoma in my country? What are the unmet clinical needs? Professor Qingqing Cai’s PTCL is a heterogeneous aggressive non-Hodgkin’s lymphoma, which is mostly advanced and progressing rapidly when first diagnosed.
Even with high-intensity treatment, the cure rate is still low
.
The most common first-line treatment for PTCL is cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or CHOP-like regimens
.
The ECHELON-2 study established the CD30-targeting antibody-drug conjugate (ADC) Verbutuximab (BV) combined with CHP as the first-line treatment for CD30-positive PTCL.
The median progression-free survival (PFS) of this program ) Reached 48.
2 months, much higher than the 20.
8 months of traditional chemotherapy
.
However, in CD30-negative patients, the best combination medication strategy still needs to be further explored
.
Patients with relapsed and refractory peripheral T-cell lymphoma (RR PTCL) still lack effective treatment drugs, and the clinical outcome is poor
.
In the era of traditional chemotherapy, the median overall survival (OS) and PFS of patients with RR PTCL were only 6.
5 months and 3.
1 months, respectively
.
How to improve the efficacy of RR PTCL patients requires more treatment drugs and strategies
.
Around the world, several new drugs are approved for the treatment of RR PTCL, such as Pratroxa, Romidepsin, Belirestat, Forodesine, Chidamide, and BV
.
However, many of the new drugs mentioned above have not yet been approved in China.
Until 2020, BV and Pratroxa are officially approved in China
.
Chidamide, as an oral histone deacetylase (HDAC) inhibitor, is the most widely used targeted drug in RR PTCL in China
.
Key Phase II studies and post-marketing studies suggest that the effective rates of chidamide in the treatment of RR PTCL are 28% and 47%, respectively, and the effective rate of combination therapy may be higher
.
However, in general, there are relatively few options for PTCL treatment drugs.
How to use existing drugs reasonably to improve the efficacy of PTCL is still a problem worthy of attention in the current clinical practice of PTCL
.
Yimaitong: At this EHA meeting, you and your team reported on a study of chidamide combined with CHOP versus CHOP in the first-line treatment of PTCL.
The preliminary data is gratifying.
Could you please interpret this study in detail? Professor Qingqing Cai we retrospectively analyzed 408 newly diagnosed PTCL patients who were treated with CHOP combined with Chidamide (C-CHOP) regimen or CHOP regimen at Sun Yat-sen University Cancer Center from January 2014 to July 2020
.
According to the IPI score, the patients were matched 1:1, 22 cases were included in the C-CHOP group, and 22 cases were included in the CHOP group
.
The usage of chidamide is 20 mg twice a week
.
Patients who achieved complete remission (CR) or partial remission (PR) after treatment received maintenance therapy with chidamide
.
The study analyzed the overall response rate (ORR), PFS, OS and adverse events (AE), and explored the effectiveness and safety of the CHOP regimen and the C-CHOP regimen as the first-line treatment of PTCL
.
The median ages of patients in the C-CHOP group and CHOP group were 54.
5 years and 56.
0 years, respectively, and 10 female patients (45.
5%) and 11 female patients (50%) were enrolled, respectively
.
In the two groups of patients, IPI 0-1 and IPI≥2 were 31.
8% (7/22) and 68.
2% (15/22), respectively
.
There was no significant difference in baseline characteristics between the two groups (P>0.
05)
.
The ORR of the C-CHOP group and CHOP group were 86.
4% and 76.
3%, respectively, and the CR rates were 68.
2% and 59.
1% (P>0.
05)
.
The median follow-up was 22.
3 months.
Compared with the CHOP group, the PFS of the C-CHOP group was significantly prolonged (less than 14.
2±5.
7 months, P=0.
035)
.
However, no difference in OS was found between the two groups (P=0.
783)
.
The most common grade 3-4 AEs in the C-CHOP and CHOP groups were hematological toxicity, including neutropenia (36.
4% vs 22.
7%), thrombocytopenia (22.
7% vs 9.
0%), and anemia (22.
7% vs 4.
5 %)
.
Studies have initially shown that in the first-line treatment of PTCL patients, the C-CHOP regimen is effective and safe, and can significantly prolong PFS, but there is no difference between OS and ORR
.
In addition, we should also pay attention to the hematological toxicity of CHOP combined with Chidamide, and further clinical research is needed
.
Yimaitong: At this EHA meeting, you also reported a comparative study of the efficacy of chidamine-containing regimen vs.
chemotherapy alone in the treatment of relapsed and refractory peripheral T-cell lymphoma.
Could you please introduce the results of the study and combine it with you What is the significance of this from your own experience? Professor Qingqing Cai This study compared the efficacy of chidamide-containing regimens and chemotherapy alone in the second-line treatment of PTCL
.
We retrospectively analyzed the clinical data of 96 patients with RR PTCL who were treated at Sun Yat-sen University Cancer Center from January 2014 to July 2020
.
The inclusion criteria were relapsed patients who had received first-line treatment in the past
.
Based on the second-line treatment plan, patients are divided into three groups: chemotherapy alone group, chemotherapy combined with chidamide, chidamide with or without other targeted drugs (targeted therapy group)
.
Compare the PFS, OS, ORR, CR rates of the three groups of patients
.
With a median follow-up of 20.
1 months, the baseline data (median age, gender, second-line IPI, PTCL subtype, CD30 expression, and EBV infection) analysis of the three groups of patients found that the chemotherapy group included more PTCL non-specific types (PTCL-NOS ) Patients, the targeted therapy group included more patients with angioimmunoblastic T-cell lymphoma (AITL), and other baseline characteristics were basically balanced among the groups
.
PFS was better in the chemotherapy combined with Chidamide group (P=0.
046), (chemotherapy alone group vs chemotherapy combined with Chidamide group vs targeted therapy group: 3.
5 months vs 4.
5 months vs 1.
8 months, P=0.
046) The median PFS in the chemotherapy plus chidamide group was 4.
5 months, compared with 3.
5 months in the chemotherapy group and 1.
8 months in the targeted therapy group
.
There was no significant difference in OS between the three groups (P=0.
912)
.
Subgroup analysis showed that chemotherapy combined with Chidamide can provide high second-line IPI (3-5 points) (P=0.
045), young patients (≤60 years old) (P=0.
027) and CD30-negative (P=0.
002) patients Bring PFS benefits
.
There was no significant difference in PFS in low second-line IPI (0-2 points), elderly patients (>60 years old), and CD30-positive patients
.
In high second-line IPI patients, chemotherapy combined with Chidamide has a tendency to prolong OS (P=0.
188)
.
The ORRs of the chemotherapy group, chemotherapy combined with Chidamide group, and targeted therapy group were 54.
8%, 64.
9%, 64.
7% (P=0.
607), and the CR rates were 16.
7%, 18.
9%, and 35.
3% (P=0.
262)
.
Compared with chemotherapy alone and targeted therapy containing chidamide, chemotherapy combined with chidamide as a second-line treatment has more PFS benefits, and chidamide should be considered in the treatment of RR PTCL
.
Yimaitong: In the past two years, there have been many advances in the treatment of PTCL, including the research results you reported at this year's EHA.
What changes will these advances bring to the treatment of PTCL? In the retrospective study of the first-line treatment of PTCL by Professor Qingqing Cai, we compared the CHOP combined with Chidamide regimen and the CHOP regimen
.
Because the IPI score is an important indicator of the prognostic risk of PTCL, it is reasonable and necessary to match the cases with 1:1 according to the IPI score
.
The results of the study suggest that CHOP combined with Chidamide can bring benefits to PFS in the first-line treatment of PTCL, which is effective and safe
.
However, a large randomized study is still needed to verify the effectiveness of Chidamide in the first-line treatment of PTCL
.
In the retrospective study of RR PTCL, we retrospectively compared the curative effects of chidamide-containing regimens and chemotherapy regimens in patients with RR PTCL.
The results of the study suggest that chidamide combined with chemotherapy can be further enhanced on the basis of chemotherapy.
It is of practical significance for the treatment of PTCL
.
However, at this stage, further randomized studies are needed to confirm the effectiveness and safety of chidamide combined with chemotherapy in patients with RR PTCL
.
In general, the current treatment of PTCL, in addition to traditional chemotherapy, needs to actively consider new drugs such as verbutuximab and HDAC inhibitors to further improve the effective rate and extend the time of disease control
.
For patients with effective treatment, hematopoietic stem cell transplantation is still an important treatment method; for some patients who are not suitable for transplantation or who refuse transplantation, maintenance therapy with targeted drugs is also an optional strategy
.
Professor Cai Qingqing, Chief Physician, PhD Supervisor, Deputy Director of the Department of Internal Medicine, Sun Yat-sen University Tumor Hospital, Head of the Lymphoma Group of the Oncology Branch of the Guangdong Medical Association, Deputy Chairman of the Youth Committee of the Oncology Branch of the Chinese Medical Association, Lymphoma Major, China Medical Education Association Deputy Chairman of the Committee, Deputy Chairman of the Lymphoma Professional Committee of the Guangdong Provincial Association of Women Physicians, Deputy Chairman of the Guangdong Anti-Cancer Association, Hematological Oncology Committee, Deputy Chairman of the Youth Committee, Beijing Cancer Society ) The corresponding author has published 14 SCI papers on Blood, Leukemia, CCR, etc.
, and presided over 3 National Natural Science Funds and a number of provincial funds stamped "Read the original text", and we will make progress together
